COST-MINIMIZATION ANALYSIS OF CAPECITABINE VERSUS UFT/LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC), ACCORDING TO THE RECOMMENDED BRAZILIAN GUIDELINES FOR HTA

被引：0

作者：

Saggia, M. G. ^{[1
]}

Nasciben, V. D. ^{[2
]}

Santos, E. V. ^{[1
]}

机构：

[1] Roche Pharmaceut, Hlth Econ, Sao Paulo, Brazil

[2] Prod Roche Quim & Farmaceut, Hlth Econ, Sao Paulo, Brazil

来源：

ANNALS OF ONCOLOGY | 2008年 / 19卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：148 / 148

页数：1

共 50 条

[21] COST-MINIMIZATION ANALYSIS OF ERLOTINIB VERSUS DOCETAXEL OR PEMETREXED AS SECOND-LINE THERAPY FOR NON-SMALL-CELL LUNG CANCER (NSCLC) FROM THE PERSPECTIVE OF A PRIVATE PAYER IN BRAZIL ACCORDING TO LOCAL HTA GUIDELINES
Santos, E. V.
Stefani, S. D.
Saggia, M. G.
ANNALS OF ONCOLOGY, 2008, 19 : 121 - 121
[22] COST-MINIMIZATION ANALYSIS OF PANITUMUMAB COMPARED WITH CETUXIMAB IN THE FIRST-LINE TREATMENT OF WILD-TYPE RAS METASTATIC COLORECTAL CANCER PATIENTS IN BRAZIL
dos Santos, R. F.
Riveros, B. S.
Nita, M. E.
Pedro, G. O.
VALUE IN HEALTH, 2016, 19 (07) : A738 - A739
[23] COST-MINIMIZATION ANALYSIS OF BEVACIZUMAB COMPARED TO CETUXIMAB AND PANITUMUMAB IN FIRST-LINE TREATMENT OF KRAS WILD-TYPE METASTATIC COLORECTAL CANCER IN FRANCE
Gherardi, A.
Masia, C.
Plommet, N.
VALUE IN HEALTH, 2016, 19 (07) : A738 - A738
[24] COST-MINIMIZATION ANALYSIS OF TRASTUZUMAB INTRAVENOUS VERSUS TRASTUZUMAB SUBCUTANEOUS FOR THE TREATMENT OF PATIENTS WITH HER2+EARLY BREAST CANCER AND METASTATIC BREAST CANCER IN GREECE
Mylonas, C.
Kourlaba, G.
Fountzilas, G.
Skroumpelos, A.
Maniadakis, N.
VALUE IN HEALTH, 2014, 17 (07) : A640 - A641
[25] COST-MINIMIZATION ANALYSIS OF BEVACIZUMAB VERSUS CETUXIMAB IN FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER IN KRAS WILD-TYPE PATIENTS IN THE SUPPLEMENTARY HEALTH CARE SYSTEM IN BRAZIL
Tsuchiya, C. T.
Kim, H. S. J.
Maximo, M. F. M.
Ramos, L. A.
VALUE IN HEALTH, 2014, 17 (07) : A641 - A641
[26] COST-EFFECTIVENESS ANALYSIS OF LAPATINIB ASSOCIATED TO CAPECITABINE VERSUS CAPECITABINE ALONE AND OF TRASTUZUMAB ASSOCIATED TO CAPECITABINE VERSUS CAPECITABINE ALONE IN THE TREATMENT OF METASTATIC BREAST CANCER UNDER THE BRAZILIAN PRIVATE HEALTH CARE SYSTEM PERSPECTIVE
Teich, V
Passos, R. B. F.
Teich, N.
Canella, M.
VALUE IN HEALTH, 2009, 12 (07) : A497 - A497
[27] Cost Analysis of Capecitabine vs 5-Fluorouracil-Based Treatment for Metastatic Colorectal Cancer Patients
De Portu, S.
Mantovani, L. G.
Ravaioli, A.
Tamburini, E.
Bollina, R.
Cozzi, C.
Grimaldi, A. M.
Testa, T. E.
Bianchessi, C.
Carteni, G.
JOURNAL OF CHEMOTHERAPY, 2010, 22 (02) : 125 - 128
[28] Initial efficacy evaluation of fruquintinib plus capecitabine versus capecitabine as maintenance treatment for metastatic colorectal cancer (mCRC): A randomized, controlled, phase Ib/II study.
Li, Wenhua
Chang, Jinjia
Wang, Chenchen
Peng, Junjie
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 119 - 119
[29] Cost comparison of two treatment regimens for metastatic colorectal cancer.: 5-fluorouracil plus leucovorin vs. capecitabine.
Arén, O
Calveira, S
Banchero, P
Barnech, A
Sosa, D
ANNALS OF ONCOLOGY, 2000, 11 : 56 - 56
[30] Capecitabine Versus Continuous Infusion Fluorouracil for the Treatment of Advanced or Metastatic Colorectal Cancer: a Meta-analysis
Zehua Wu
Yanhong Deng
Current Treatment Options in Oncology, 2018, 19

← 1 2 3 4 5 →